Company Profile
Blueprint Medicines Stock Price, News & Analysis
- Ticker:
- BPMC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for BPMC.
Company overview
Business overview
Blueprint Medicines is a precision-oncology and rare-disease company with a strong focus on kinase biology and mast-cell disease.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Blueprint sits in targeted-therapy biotechnology.
Business Model Characteristics
Its model combines commercial product growth, targeted oncology development, and continued investment in rare-disease programs.
Position Within the Biotechnology Landscape
Blueprint is a high-quality targeted-therapy biotech whose stock reacts to launches, data, and strategic optionality.
Future catalysts
Blueprint Medicines's catalysts are Ayvakit in systemic mastocytosis and BLU-808 as the next immunology growth option. The market will care about whether the mast-cell franchise can keep expanding while the next program de-risks the pipeline.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Blueprint Medicines do?
Blueprint Medicines is a precision-oncology and rare-disease company with a strong focus on kinase biology and mast-cell disease.
On which exchange is BPMC stock listed?
Blueprint Medicines (BPMC) is associated with NASDAQ, United States, Biopharma.
What is BLU-808?
Blueprint Medicines's catalysts are Ayvakit in systemic mastocytosis and BLU-808 as the next immunology growth option.
Which conditions is Blueprint Medicines targeting with BLU-808?
Blueprint Medicines is associated with oncology, immunology based on its company overview and current catalyst commentary.
How does Blueprint Medicines describe recent progress with BLU-808?
Blueprint Medicines's catalysts are Ayvakit in systemic mastocytosis and BLU-808 as the next immunology growth option.
What is Blueprint?
Blueprint Medicines is a precision-oncology and rare-disease company with a strong focus on kinase biology and mast-cell disease.
What should investors watch for with Blueprint?
Blueprint Medicines's catalysts are Ayvakit in systemic mastocytosis and BLU-808 as the next immunology growth option.
What is Medicines?
Blueprint Medicines is a precision-oncology and rare-disease company with a strong focus on kinase biology and mast-cell disease.